Introduction
Prostate cancer is the most commonly diagnosed cancer in American men representing one third of all new cancer cases each year. This means that one of six men is being diagnosed with prostate cancer over his lifetime. Early-stage androgen-sensitive prostate cancer is manageable with androgen depletion therapy. However, approximately one third of the prostate cancer patients have micrometastatic disease at the time of diagnosis. This group of patients will eventually progress to clinically detectable metastatic and androgen-independent diseases at which point the median survival is only 12-15 months (Denmeade and Isaacs, 2004) . Therefore, metastatic prostate cancer remains the main cause of prostate cancer-related death in men. Identification of agents that inhibit cancer cell growth could therefore be particularly interesting to fight prostate cancer.
Metformin belongs to the biguanide class of oral hypoglycemic agents and is a widely used antidiabetic drug now prescribed to almost 120 million of people in the world. The main use of metformin is in the treatment of type II diabetes and beneficial effects have been observed in the treatment of polycystic ovarian syndrome (PCOS; Lord et al., 2003) , nonalcoholic fatty liver disease (NAFLD; Marchesini et al., 2001 ) and premature puberty (Ibanez et al., 2006) . In addition to its efficacy in lowering glucose levels, metformin has the clinical advantages of inducing no risk of hypoglycemia and very rarely causes lactic acidosis. Importantly, recent evidence pointed out that metformin may reduce the risk of cancer (Evans et al., 2005) . Although the mechanism of action of metformin has been very well studied in liver, adipose tissue and heart, its role in cancer cells is poorly known. Among the beneficial effects of metformin on metabolism a reduction of hepatic glucose production, increased glucose utilization and increased fatty acid oxidation were described. Similar effects on metabolism are observed for 5 amino-imidazol-4-carboxamide-1-b-4-ribofuranoside (AICAR), which is known to be taken up into cells and converted to the monophosphorylated form ZMP, which mimics an increase of AMP intracellular levels. Both metformin and AICAR activate the AMPactivated protein kinase (AMPK) pathway. AMPK is a serine/threonine kinase and a member of a metabolitesensing protein kinase family found in all eukaryotic cells (Kahn et al., 2005) . AMPK is a cellular fuel sensor pathway sensitive to the increase of the AMP/ATP ratio. This pathway is a potent mediator of exercise induced glucose uptake in skeletal muscle (Hardie, 2003) . Once activated AMPK phosphorylates and inactivates a number of metabolic enzymes involved in ATP-consuming cellular events such as fatty acid and protein synthesis involving the acetyl-coenzyme A carboxylase (ACC). Furthermore, AMPK activation has been shown to inhibit the mTOR pathway and S6K1 phosphorylation implicated in protein synthesis suggesting that this pathway may regulate cell proliferation. Recently, Zakikhani et al. (2006) showed that metformin inhibits MCF7 cancer cell growth in vitro and this effect was reverted by AMPK knock-down. However, the cellular mode of action and the cellular targets of metformin in cancer cells remain unknown.
Mammalian cell proliferation is governed by the cellcycle machinery. Cyclins and cyclin inhibitors tightly control cell cycle progression. One of the main checkpoint is the G 1 /S transition. Cyclin D1 plays a critical role in the regulation of proliferation by adjusting its expression levels to reflect the proliferative signaling environment of the cell, and by regulating the cell cycle control machinery accordingly. Cyclin D1 functions are primarily to bind and activate the cyclin dependent kinase (CDK) 4/6, which then phosphorylates the retinoblastoma protein (Rb). Upon phosphorylation Rb releases the transcription factor E2F, which is then able to activate the transcription of genes required for G 1 /S phase transition (Matsushime et al., 1994; Weinberg, 1995) . The cyclin D1/CDK4/6 complex is also able to sequester p27 kip1 and other CDK inhibitory proteins, thereby neutralizing their inhibitory capacity for cyclin E/CDK2 (Sherr and Roberts, 1995) whose activity is required for G 1 /S transition (Hunter, 1997) .
Here we show that metformin inhibited human prostate cancer cell growth, did not induce apoptosis and blocked cell cycle in G 0 /G 1 . It inhibited cyclin D1 expression and pRb phosphorylation independently of the fuel sensor pathway AMPK. More importantly we showed that daily treatment of mice with metformin decreased tumor growth in a xenograft model.
Results

Metformin inhibits human prostate cancer cell growth
In order to determine whether metformin affects human prostate cancer cell proliferation we analysed the effect of the drug on three cancer cell lines: DU145, PC-3 and LNCaP and one normal cell line: P69 (immortalized human primary prostate epithelial cells). Cells were grown in 10% fetal bovine serum (FBS), treated with metformin (1 and 5 mM) and AICAR (5 mM) as a control. The MTT viability assay was performed 4 days after the addition of the agents (see Materials and methods). AICAR reduced cell viability by 70% in the four cell lines. Similarly, metformin led to a dose dependent and strong inhibition of cell proliferation in all prostate cancer cell lines with 52, 54 and 38% decrease of cell viability in LNCaP, DU145 and PC3 respectively with 5 mM metformin. On contrary, metformin had a moderate effect on P69 cells with only a 20% decrease of cell viability, which is significantly less than the average inhibition observed with the prostate cancer cell lines (48% dashed line in Figure 1a ). These results suggest that metformin may specifically affect cancer cells proliferation compared to normal cells. We also found that metformin inhibited HT-29 (colon cancer cell line) by 38% and more moderately MCF-7 (breast cancer cell line) by 29% (Figure 1a ). To establish a direct relationship between the decrease of cell viability and inhibition of cell proliferation, we followed the course of proliferation over 3 days after the addition of metformin and AICAR in LNCaP cells. Metformin (1 and 5 mM) led to a decrease of cell proliferation in a dose dependent manner and AICAR decreased the percentage of viable cells below the seeding density on day 2. All together, these results show that metformin inhibits prostate cancer proliferation.
Metformin does not induce apoptosis
In order to determine if metformin induces apoptosis in human prostate cancer cells, we performed a caspase 3 assay. AICAR is known to induce apoptosis while metformin was shown to protect endothelial cells from apoptosis (Detaille et al., 2005; Kim et al., 2007) . LNCaP cells were incubated with metformin, AICAR and staurosporine as a control. AICAR and staurosporine induced a strong increase of caspase 3 activity while metformin had no effect on caspase 3 activity (Figure 2a) . Then we performed an annexin V-FITC labeling assay and found that metformin at 1 and 5 mM did not affect the amount of annexin V positive cells. On contrary, AICAR increased the percentage of cell positive for annexin V (Figure 2b) . Similarly, metformin did not induce apoptosis in DU145 and PC-3 cells (data not shown). These results show that apoptosis is not implicated in the metformin-induced inhibition of proliferation.
Metformin blocks cell cycle in G 0 /G 1 We then asked whether metformin affects cell cycle. To check this hypothesis, LNCaP cells were incubated for 24 h in 1.5% DMSO to arrest cells in G 0 /G 1 (Loubat et al., 1999) . After the removal of DMSO, FBS was added to the arrested cells for 24 h in presence or not of metformin. FBS led to a significant reduction of cells in G 0 /G 1 and an increase of the percentage of cells in the S phase, whereas in presence of metformin the cells failed to enter the S phase and were blocked in G 0 /G 1 . As shown in Figure 3a we observed the same percentage of cells in G 0 /G 1 and S phase in arrested cells as in presence of metformin. These results indicate that metformin prevents the mitotic effect of FBS. In order to determine whether metformin can inhibit the cell cycle in dividing cells, we treated proliferating LNCaP cells with 5 mM metformin for different durations. After the addition of the antidiabetic agent, an increasing number of cells started to accumulate in G 0 /G 1 ; 80% after 24 h and 93% by 72 h (Figure 3b ). In parallel, we observed a reduction in the percentage of cells in the S and G 2 /M phases.
We examined the protein level of cyclin D1 a key protein implicated in the transition of the G 0 /G 1 phase. Cyclin D1 protein level slightly declined 8 h after the addition metformin and is no longer detectable after 48 h (Figure 3c ). We then analysed the expression and the phosphorylation of other proteins implicated in the G 0 /G 1 transition. In arrested cells, metformin prevented the increase of pRb phosphorylation, cyclin D1 and E2F1 protein levels observed in cells treated with FBS. Furthermore, p27 kip expression remained elevated in cells treated with the antidiabetic agent ( Figure 3d ). In proliferating cells the level of phosphorylated pRb decreased progressively as well as cyclin D1 and E2F1 protein levels. On contrary, p27 kip protein level increased upon metformin treatment in proliferating LNCaP cells ( Figure 3d ). We studied by quantitative PCR the expression of E2F1 and cyclin D1 mRNA, metformin led to a significant reduction of both mRNA after 24 h suggesting that metformin affects mRNA levels in LNCaP cells ( Figure 3e) . Cyclin D1 protein level was also examined in other cancer cell lines and similarly to LNCaP metformin decreased cyclin D1 protein level in DU145 and HT-29 and to a less extent in MCF-7 cells ( Figure 3f) . These results clearly demonstrate that metformin affects the expression and the phosphorylation of key proteins of the cell cycle and leads to an arrest in G 0 /G 1 in human prostate cancer cells. The antiproliferative effect of metformin is not mediated by the AMPK pathway The effects of metformin have been essentially attributed to its ability to activate the AMPK pathway. Thus, we investigated if metformin activates the AMPK pathway in prostatic cell lines. Metformin induced the phosphorylation of AMPK on Thr 172 in LNCaP ( Figure 4a ) in PC-3 and DU145 cells (data not shown) and this activation lasted for at least 8 h. In order to determine if the antiproliferative effect of metformin is mediated by the AMPK pathway, we blocked this pathway using siRNA directed against the two catalytic subunits of AMPK: a1 and a2. Both siRNA efficiently diminished the expression of a1 and a2 proteins in LNCaP cells (Figure 4b ). In cells transfected with control siRNA, metformin induced the phosphorylation of ACC, a substrate of AMPK (Figure 4c , lane siRNA control). Inhibition of AMPK expression by specific siRNA blocked the phosphorylation of ACC after metformin treatment (Figure 4c ). However, it did not prevent the inhibition of cyclin D1 expression and the decrease of pRb phosphorylation. Similar results were obtained in DU145 cells using the same siRNAs (data not shown). AMPK activation has been shown to inhibit the mTOR pathway and S6K1 phosphorylation implicated in protein synthesis suggesting that this pathway may regulate cell proliferation. Thus, we analysed S6K1 phosphorylation on Thr 389 , interestingly metformin downregulated S6K1 phosphorylation even when AMPK is inhibited (Figure 4c ), indicating that the antiproliferative effect of metformin is accompanied by a downregulation of the mTOR pathway but is independent of AMPK. When a flow cytometry analysis was performed in cells transfected with a1 and a2 AMPK siRNA, inhibition of AMPK did not prevent the G 0 /G 1 cell cycle induced by metformin (Figure 4d ). All together, this series of experiments demonstrated at the protein and cellular level that the AMPK pathway does not mediate the effect of metformin on cell cycle.
Metformin inhibits soft agar growth and in vivo tumor proliferation Numerous studies have shown that growth in soft agar is a very good model to study tumorigenicity and is closely associated with the transformed property of cells (Sharan et al., 1997; Bost et al., 1999) . To determine whether metformin inhibits anchorage-independent growth, we performed a soft-agar colony formation assay in absence or presence of 1 and 5 mM metformin renewed daily. After 3 weeks, the cells were stained by addition of a tetrazolium dye and incubated at 37 1C. LNCaP and DU145 cells make small colonies in soft agar (Figure 5a ). Importantly, we evidenced that ). On contrary to phenformin a biguanide which induces lactose acidosis (Campbell, 1985) , metformin is widely prescribed to diabetic patients without major reported side effect. Metformin had no toxic effect on mice whatever the Metformin decreases prostate tumor growth I Ben Sahra et al type of administration and did not affect the animal weight (data not shown). On the basis of the integrated values of the tumor growth curves, metformin administrated i.p. or orally led to a substantial inhibition of tumor growth by 35 and 55%, respectively (Figures 5b and c) . To examine the significance of the differences between growth curves in this study, all the measurements of tumor volume for each growth curve from the start of the treatment to the end, typically about 30 observations, were analysed by Kruskal-Wallis one-way analysis. Thus, the 55 and 35% inhibitions of growth rates observed with metformin are significant when compared with control with Po0.003.
In order to determine if metformin affects cyclin D1 protein levels in vivo, we analysed cyclin D1 expression in tumors from the xenograft experiments. In both conditions, i.p. and oral administration, metformin reduced significantly cyclin D1 protein levels in treated tumors compared to controls (Figure 5d ). These results suggest that similar to our in vitro observations, metformin decreases tumor growth through a reduction of cyclin D1 protein levels.
Discussion
Recent data suggest that metformin could protect from cancer (Schneider et al., 2001; Evans et al., 2005) and inhibit breast and glial cancer cell proliferation in vitro (Zakikhani et al., 2006) . Here we show that metformin not only is a very potent inhibitor of human prostate cancer cell growth, but also inhibits tumorigenesis in a xenograft model when it is administrated orally or i.p. The role of metformin in glucose and fatty acid metabolism is very well known. It stimulates glucose uptake and increases fatty acid oxidation in muscle and liver with no side effect when administrated at the dose of 1-3 mg per day. However, the mode of action and the biological consequences of this antidiabetic drug on cancer cells are poorly understood. Metformin and AICAR have similar effects on metabolism and both activate AMPK, which phosphorylates ACC (Zhou et al., 2001; Ruderman et al., 2003) .
Here we show that AICAR and metformin inhibit cellular proliferation through different mechanisms in human prostate cancer cells. AICAR induces apoptosis while metformin blocks cell cycle in G 0 /G 1 , which is correlated with a decrease of expression of cyclin D1, E2F1 and phosphorylation of pRb. Recent studies performed in adipocyte and b pancreatic cells have shown that AICAR induces or enhances apoptosis via the AMPK pathway (Dagon et al., 2006; Kim et al., 2007) . On contrary, several studies demonstrated that metformin protects against apoptosis in normal cells. An et al. (2006) showed that metformin reduces highfat-induced cardiac cell death, through inhibition of ceramide synthesis. Similarly, metformin was shown to prevent high glucose-induced endothelial cell death (Detaille et al., 2005) . This discrepancy suggests that even though they both activate the AMPK pathway, AICAR and metformin mediate their effects through different mechanisms.
Our results suggest that cyclin D1 and pRb, two major regulators of cell cycle, could be intracellular targets of the metformin-mediated antiproliferative effect in human prostate cancer cells. The cyclin D1 gene (CCND1) is amplified and/or overexpressed in several types of human cancer (Alao, 2007) . Cyclin D1 mRNA levels are increased in both primary prostate cancer samples (Han et al., 1998) and androgenindependent bone metastasis (Drobnjak et al., 2000) . Furthermore, increased expression of cyclin D1 in LNCaP enhanced cell growth and tumorigenicity (Chen et al., 1998; Perry et al., 1998) . Therefore, inhibition of cyclin D1 may be an interesting molecular target to control tumor proliferation (Zhang et al., 2007) . Our study reveals that metformin may represent a valuable potential therapeutic agent to block prostate tumor growth. The regulation of cyclin D1 activity is primarily dependent upon its expression level. This level is controlled by the regulation of gene expression, mRNA stability and translation. The stability of cyclin D1 protein plays a major role in the regulation of its expression. Phosphorylation of the cyclin on Thr 286 results in the rapid proteasomal degradation of the protein (Diehl et al., 1998) . Whether or not metformin may lead to the phosphorylation of cyclin D1 remains to be determined in future studies. In addition to cyclin D1, metformin decreased E2F1 protein level and strongly inhibited pRb phosphorylation in LNCaP cells. Activation of E2F transcription factors, through disruption of the Rb tumor-suppressor gene, is a key event in the development of many human cancers. It is well established that elevated expression of E2F1 is associated with malignant transformation in prostate cancer (Davis et al., 2006; Libertini et al., 2006) . On contrary, downregulation of this transcription factor is associated with a decrease of cell proliferation (Erlich et al., 2006; Park et al., 2006) .
We showed that metformin activates the AMPK pathway in human prostate cancer cells but mediates its effect independently of AMPK. Here, using siRNA against the two catalytic subunits of AMPK, we showed that inhibition of the AMPK pathway did not reverse the antiproliferative effect of metformin. These results are emphasized by the fact that the antidiabetic drug inhibited S6K1 phosphorylation in the absence of the two catalytic units of AMPK suggesting that the antiproliferative effect of metformin are mediated through the mTOR pathway independently of AMPK. Our study contradicts the results obtained in MCF-7 by Zakikhani et al. (2006) who showed that metformin inhibits cell growth via the a1 AMPK subunit in MCF-7 breast cancer cells. This disparity may be due to a cell specific effect. Similar to Zakikhani et al., we observed that metformin inhibits MCF-7 proliferation by 30%, however, we evidenced a stronger antiproliferative effect in prostate cancer cells compared to breast cancer cells. This marked difference between cell lines was confirmed by the effect of metformin on cyclin D1 protein level which was moderately decreased in MCF-7 cells compared to prostate cancer cells (Figures 1 and 4) . The use of metformin has been extremely useful to study the AMPK pathway but like any pharmacological tools they may have other unknown function independently of their initial action. Indeed, biguanides do not directly activate AMPK in cell free assays (Hawley et al., 2002) , but instead appear to inhibit complex I of the respiratory chain leading to an increase in AMP:ATP ratio (El-Mir et al., 2000) . Effects of biguanides could therefore be secondary effects of ATP depletion, rather than effects of AMPK activation per se. Other groups have evidenced that metformin mediates its effects independently of AMPK. For example, Hue's group has recently shown that effects of metformin and AICAR on the function of glucokinase in hepatocytes are still observed in mice lacking a1 and a2 catalytic units (Guigas et al., 2006) . These considerations highlight the increasing importance of confirming that the effects of metformin are mediated or not by AMPK using appropriate molecular tools targeting both catalytic units. We show that metformin decreases S6K1 phosphorylation suggesting that the mTOR pathway is involved in the metformin effect. Further studies are therefore required to determine which proteins mediate the intracellular effect of metformin on the mTOR pathway. Implication of the tumor suppressor LKB1 (Collins et al., 2000) and other inhibitors of mTOR should be investigated. Furthermore, we cannot exclude that part of the observed effect is mediated by AMPK as siRNA did not completely abolished the protein expression.
Participation of metformin in the control of cell metabolism is well known for example, it increases significantly glycolysis. We have shown that metformin increases lactate production in prostate cancer cells and that glucose deprivation does not prevent metformin-induced cell cycle arrest (data not shown). Nevertheless, it would be interesting to determine if the metabolic consequences of metformin are related to the effects on cell cycle arrest.
In vivo experiments clearly show that metformin given orally or i.p. significantly decreases prostate tumor growth in a xenograft model. This result is of particular importance since it is the first time that metformin is shown to inhibit prostate tumor growth in a xenograft model. Schneider et al. (2001) showed that metformin reduced the number of pancreatic malignant lesions in hamsters treated with metformin. However, the concentration administrated to the animal is 120 times higher than the concentration used in our study (Schneider et al., 2001) . Here, with the dosage used for patients, we obtained a strong inhibition of tumor growth. Metformin is widely used for the treatment of type II diabetes and without having significant side effects at the dose used in this study. Therefore, the remarkable efficiency of metformin to inhibit prostate cancer cell proliferation and tumor growth may have important implications in the treatment of prostate cancer. Furthermore, it will be of interest to determine if this effect is relevant to other cancer cell lines.
Materials and methods
Cell lines and culture conditions Cells were cultured in RPMI 1640 (LNCaP and P69) or Dulbecco's modified Eagle's medium (DMEM; PC-3, DU145, DU-145 and HT-29) containing 4500 mg ml À1 glucose supplemented with 10% fetal bovine serum (FBS) and 100 U ml À1 penicillin, 100 mg ml À1 streptomycin, and 2 mM glutamine at 37 1C and 5% CO 2 . The P69 cell line was derived by immortalization of human primary prostate epithelial cells with simian virus-40 T antigen (Plymate et al., 1996) and were grown in RPMI 1640 with 10% FBS. Cell culture media were obtained from Invitrogen (Carlsbad, CA, USA). All prostate cancer cells were a gift of Dr Dan Mercola (UC Irvine, CA, USA).
Chemicals AICAR (Toronto Research Chemicals Inc., North York, Ontario, Canada) and Metformin (Sigma Chemical Co., St Louis, MO, USA) were dissolved in culture media and stored at À20 1C.
Western blotting analysis
Cell extracts were prepared using lysis buffer as described previously (Aouadi et al., 2006) . Immunoblotting was performed with antibodies against AMPK phosphorylated on Thr172, AMPK, ACC, phospho ACC, S6K1 and phospho S6 K1 (Cell Signaling Technology, Danvers, MA, USA), pRB and cyclin D1 (BD Biosciences Pharmingen, San Jose, CA, USA), E2F1, p27, a1 and a2 AMPK (Santa Cruz Biotechnology, Santa Cruz, CA, USA), a tubulin (Sigma Chemical Co.).
Real-time quantitative PCR
Quantitative RT-PCR was performed with the ABI Prism7000 (Applied Biosystem, Foster City, CA, USA) as previously described (Aouadi et al., 2006) . The relative amounts of the different mRNAs were quantified by using the second derivative maximum method. RPLP0 was used as an invariant control, and the relative quantification for a given gene was corrected to RPLP0 mRNA values. The results were expressed relative to the control condition, which was arbitrary assigned a value of 1.
Cell cycle analysis by FACS Cells were trypsinized, washed twice in ice-cold PBS, and resuspended in 200 ml citrate buffer (250 mM sucrose, 40 mM Tri-sodium citrate, 5% dimethyl sulfoxide (DMSO) adjusted to pH 7.6 with 40 mM acetic acid). Propidium iodide (40 mg ml
À1
) solution was added to the cells and incubated for 45 min in the dark at 4 1C prior to analysis.
Cell proliferation assay Cells were seeded at 2.10 3 per well in 96-well plates and incubated in medium containing 10% FBS. 24 h after seeding, cells were treated or not with metformin (1 or 5 mM) or AICAR (5 mM). After 3 days, the tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) was added to the wells, cells were incubated for 4 h at 37 1C and the optical density was measured.
Cell transfection
LNCaP and DU145 were transfected with siRNA targeting the a1 and a2 AMPK isoforms (Santa Cruz Biotechnology) or a negative control siRNA using Lipofectamine 2000 (Invitrogen). The day after the transfection, 5 mM metformin was added to the medium and proteins were extracted 48 h after the addition of metformin.
Tumor xenograft model LNCaP cells were inoculated s.c. with BD matrigel matrix (BD Biosciences, Bedford, MA, USA) in 5-week-old female nude mice on both flanks (10 6 or 2 Â 10 6 cells per site). Treatment with metformin was started when the average tumor volumes reached 50 mm 3 . Five mice were used per group. Metformin was dissolved in drinking water (200 mg ml À1 ) or inoculated i.p. (1 mg per day). Tumor size was measured weekly during 5 weeks and tumor volume was calculated using the formula (p/6) Â A Â B 2 (A ¼ larger diameter of the tumor, B ¼ smaller diameter of the tumor) as described previously (Bost et al., 2000) .
Caspase 3 assay
After the addition of metformin, AICAR or staurosporine (Sigma Chemical Co.), cells were lysed for 30 min at 4 1C in lysis buffer (50 mM HEPES pH 8, 150 mM NaCl, 20 mM ethylene diaminetetraacetic acid (EDTA), 1 mM phenylmethylsulphonylfluoride (PMSF), 10 mg ml À1 leupeptin, 10 mg ml À1 aprotinin and 0.2%. Triton X-100), and lysates were cleared at 10 000 g for 15 min at 4 1C. Each assay (in triplicate) was performed with 50 mg of protein prepared from control or stimulated cells. Cellular extracts were then incubated in a 96-well plate, with 0.2 mM of Ac-DEVD-AMC (caspase 3 substrate) for various times at 37 1C as described previously (Herrant et al., 2004) . Caspase activity was measured in presence or not of Ac-DEVD-CHO (caspase 3 inhibitor) using a fluorometer. Enzyme activities were determined in relative intensity per minute and per milligram of protein.
Annexin V/PI staining assay Apoptosis was assessed by measuring membrane redistribution of phosphatidylserine using an annexin V-FITC apoptosis detection kit (Roche Diagnostics, Mannheim, Germany). According to the protocol kit, cells were collected, washed twice with PBS and resuspended in 500 ml of staining solution containing FITC-conjugated annexin V antibody and propidium iodide (PI). After incubation on ice for 30 min, cells were analysed by flow cytometry. Basal apoptosis and necrosis were identically determined on untreated cells.
Statistical analysis
For MTT test, statistical analyses were done using Student's t-test. Tumor volumes (metformin treated versus control) were compared using Kruskal-Wallis test.
Abbreviations AICAR, 5 amino-imidazol-4-carboxamide-1-b-4-ribofuranoside; ACC, Acetyl Coenzyme-A Carboxylase; AMPK, AMPactivated protein kinase; pRb, retinoblastoma protein.
